Loading
A phase 2 trial of Orca-T in myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., now recruiting.
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 2 interventional study registered as NCT07216443 by Orca Biosystems, Inc., with 80 participants planned, started 2025-12-09 and due to reach its primary completion in 2027-11. Interventions recorded: Orca-T.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Orca Bio, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/